Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/31/2025 | $19.00 | Mkt Outperform | JMP Securities |
| 1/7/2025 | $30.00 | Buy | TD Cowen |
| 12/18/2024 | $22.00 | Buy | BofA Securities |
| 3/11/2022 | $48.00 → $42.00 | Buy | Needham |
| 12/10/2021 | $50.00 → $48.00 | Buy | Needham |
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that Jeb Ledell has joined the Company as Chief Operating Officer (COO). Mr. Ledell is an accomplished public company COO with a track record of driving operational excellence and strategic growth within the biotechnology industry. "I am pleased to welcome Jeb to KalVista at this key time in our evolution. His extensive experience in leading teams and driving efficiency within companies like ours makes him a valued addition to the team as we continue to evolve into a commercial entity," said Ben Palleiko, Chief Executive Officer of KalVista. "I am confident that his proven skills will help us to achieve our goal of delivering s
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that Laurence Reid, Ph.D., has been appointed to the Company's Board of Directors, effective immediately. Dr. Reid brings more than three decades of experience with a track record of leadership and company-building success. "I am pleased to welcome Dr. Reid, with his deep expertise in high-growth biotech companies, to the KalVista Board of Directors," said Ben Palleiko, Chief Executive Officer of KalVista. "His extensive biopharmaceutical and strategic experience will be a tremendous asset as the Company continues to progress sebetralstat towards global market approval and commercialization." "I am excited to join the KalVist
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that Brian Piekos has joined the Company as Chief Financial Officer (CFO). Mr. Piekos is an experienced public company CFO who brings a demonstrated track record of successfully leading companies across the biotechnology sector. "Brian's deep industry experience and expertise in managing financial and capital strategies makes him a strong addition to KalVista as we prepare for the commercialization of sebetralstat," said Ben Palleiko, Chief Executive Officer at KalVista. "I'm excited to welcome Brian to KalVista, as he shares our commitment to patients and a results-driven approach to business excellence." "I am excited to join
S-8 - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)
8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)
8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)
JMP Securities initiated coverage of KalVista Pharmaceuticals with a rating of Mkt Outperform and set a new price target of $19.00
TD Cowen initiated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $30.00
BofA Securities initiated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $22.00
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
– Sebetralstat 300 mg achieved beginning of symptom relief in 1.6 hours – – Safety profile comparable to placebo – – On track for submission of new drug application to U.S. FDA in the first half of 2024 – – Conference call to discuss trial results today at 8:30 a.m. ET – KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced positive results from the phase 3 KONFIDENT clinical trial demonstrating statistically and clinically significant efficacy of sebetralstat as oral on-demand therapy for hereditary angioedema (HAE). KONFIDENT was the l
SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)
SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)
SC 13G - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)
– Claims data show 40% of patients on long-term prophylaxis have gaps in prescription refills, leading to greater on-demand use and higher rate of LTP discontinuation- -Data from KONFIDENT-S show patients on LTP average 1.7 HAE attacks per month and symptom relief for treated attacks in median 1.3 hours - –Results confirm sebetralstat effective for on-demand treatment of attacks regardless of type of LTP therapy used, including an all-oral regimen– KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced the presentation of novel data related to long-term prophylaxis and sebetralstat at the Western Society of Allergy, Asthma & Immunology (WSAAI) 2025 Annual Meeting taking place i
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the compensation committee of KalVista's board of directors granted fifty-two newly-hired employees inducement options to purchase an aggregate of 261,000 shares of KalVista common stock on February 3, 2025 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock on the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject to the new employee's continued ser
–Orphan drug designation paves the way for potential of sebetralstat to be first oral on-demand treatment for HAE in Japan– – Submission advances Company's strategic plan to address unmet needs in HAE on global scale– KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted sebetralstat Orphan Drug Designation. The Company has also submitted a New Drug Application (NDA) for sebetralstat to the Agency. If approved, sebetralstat, a novel, investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) attacks in adults and adolescents aged 12 years and older, would be th